drugset

drugset / Trial / NCT05087069

Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics of BV100 in Healthy Male Subjects

NCT05087069 ↗

Phase 1 Completed 16 enrolled BioVersys SAS Nuvisan · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

Safety and tolerability and Pharmacokinetics of multiple doses of BV100 in healthy volunteers

Timeline

Start: 2021-10-08
Primary completion: 2022-04-08
Completion: 2023-01-12

Publications

Kemmer C, Hirsch M, Reh C, Davila M, Jung F, Husband L, Dale GE. Single-ascending and multiple-ascending dose study of the pharmacokinetics, safety, and tolerability of BV100 (rifabutin for infusion) in healthy volunteers. Antimicrob Agents Chemother. 2026 Apr;70(4):e0158225. doi: 10.1128/aac.01582-25. Epub 2026 Mar 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifabutin	Small molecule	—	Intravenous

Indications

No indication recorded.